The Efficacy Of Mamajjaka Ghanvati Compared With Conventional Treatment Along With D4 Combination In The Management Of Madhumeha(Type 2 Diabetes Mellitus)

Comparative Clinical Study On The Efficacy Of Mamajjaka Ghanvati Compared With Conventional Treatment Along With D4 Combination In The Management Of Madhumeha(Type 2 Diabetes Mellitus) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065606

Enrollment

Registered

2024-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender in the age group of 20-79 yearsxxiii. 2. Patients with classical signs and symptoms of Madhumeha/T2DM. 3. Glycosylated haemoglobin (HbA1C) = 6.5%-12%. 4. Fasting blood sugar (FBS) = 126 mg/dl up to 250 mg/dl 5. Postprandial blood sugar (PPBS) = 200 mg/dl up to 450 mg/dl NOTE: In the above given criteria (2-5) there is one should be present and HbA1C Must be = 6.5%. 6. BMI = 25 7. Waist-Hip ratio (central obesity): Male - = 0.9 Female - = 0.85 8. Early diagnosed Diabetic patients (Maximum 3 years of diabetic history) are to be included as per following criteria: • Patients who have taken conventional medicine and whose sugar levels are raised and fall within the inclusive criteria mentioned above, and who are willing to take Ayurvedic treatment will be taken into group A. • Patients who have not taken any conventional medicine for more than last 3 months, whose sugar levels are raised and fall within the inclusive criteria mentioned above, and who are willing to take Ayurvedic treatment will be taken into group B.

Exclusion criteria

Exclusion criteria: • Patients with diagnosed chronic liver disease. • Patients having insulin dependent DM (type 1) and receiving insulin. • Chronic complications like microvascular and macrovascular derangements. • Hyper or Hypothyroidism, Hypertension. • Pregnant women / lactating mothers. • Participation in other clinical studies in past 12 week.

Design outcomes

Primary

Measure	Time frame
20-30% Reduction in the level of glycosylated haemoglobin (HbA1C)Timepoint: 120 days	—

Secondary

Measure	Time frame
• Reduction in the level of FBS & PPBS. • Changes in the level of BMI and WAIST-HIP ratio. • Improvement in the signs and symptoms of Madhumeha. • Improvement in the quality of life.Timepoint: 120 days	—

Countries

India

Contacts

Public ContactDr Jasani Nency Rameshbhai

All India Institute Of Ayurveda

mahtorajaram@yahoo.com8877033663

Outcome results